Peripheral T-Cell Lymphomas Pipeline 2024 | Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Dizal Pharmaceuticals

 Breaking News
  • No posts were found

Peripheral T-Cell Lymphomas Pipeline 2024 | Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Dizal Pharmaceuticals

Peripheral T-Cell Lymphomas Pipeline 2024 | Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Dizal Pharmaceuticals

DelveInsight’s, “Peripheral T-Cell Lymphomas Pipeline Insight 2024” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Peripheral T-Cell Lymphomas pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peripheral T-Cell Lymphomas therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Peripheral T-Cell Lymphomas Pipeline. Dive into DelveInsight’s comprehensive report today! @ Peripheral T-Cell Lymphomas Pipeline Outlook

Key Takeaways from Peripheral T-Cell Lymphomas Pipeline Report

  • July 2024:- National Cancer Centre, Singapore– Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma. The goal of this clinical trial is to evaluate the efficacy and safety of Pembrolizumab in combination with Olaparib in participants with relapsed/refractory Peripheral T-cell Lymphoma (PTCL).
  • July 2024:- Chengdu Zenitar Biomedical Technology Co., Ltd– An Open-Label, Multicenter Phase IIa Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Puesta Mesylate for Injection for the Treatment of Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma.
  • DelveInsight’s Peripheral T-Cell Lymphomas Pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Peripheral T-Cell Lymphomas treatment.
  • The leading Peripheral T-Cell Lymphomas Companies such as Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., LTD, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co. Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc., and others.
  • Promising Peripheral T-Cell Lymphomas Therapies such as Etoposide, Prednisolone, Romidepsin, Ixazomib, Chidamide, and others.

Stay ahead with the most recent pipeline outlook for Peripheral T-Cell Lymphomas. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Peripheral T-Cell Lymphomas Treatment

Peripheral T-Cell Lymphomas Emerging Drugs Profile

  • HBI-8000: HUYA Bioscience International

The novel epigenetic drug, HBI-8000, is a member of the benzamide class of histone deacetylase inhibitors (HDACIs), working by controlling how tightly DNA is wound around histone proteins, which regulate gene expression. This alters the expression of several proteins involved in processes that arrest the growth of cancer cells, increase tumor immunity and change the tumor microenvironment. Evidence suggests that this mechanism increases the efficacy of other cancer agents such as checkpoint inhibitors.

Explore groundbreaking therapies and clinical trials in the Peripheral T-Cell Lymphomas Pipeline. Access DelveInsight’s detailed report now! @ New Peripheral T-Cell Lymphomas Drugs

Peripheral T-Cell Lymphomas (PTCL) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Intra-tumoral
  • Molecule Type

Peripheral T-Cell Lymphomas Products have been categorized under various Molecule types such as

  • Monoclonal antibodies
  • Immunoglobulins
  • Small molecules
  • Pyrimidines
  • Proteins and Peptides
  • Product Type

Unveil the future of Peripheral T-Cell Lymphomas Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Peripheral T-Cell Lymphomas Market Drivers and Barriers

Scope of the Peripheral T-Cell Lymphomas Pipeline Report

  • Coverage- Global
  • Peripheral T-Cell Lymphomas Companies- Acrotech Biopharma LLC, HUYA Bioscience International, Seattle Genetics, Inc., Akeso Pharmaceuticals, Inc., Shandong New Time Pharmaceutical Co., LTD, Verastem, Inc., Genor Biopharma Co., Ltd., CerRx, Inc., Shanghai YingLi Pharmaceutical Co. Ltd., Dizal Pharmaceuticals, Kura Oncology, Inc., and others.
  • Peripheral T-Cell Lymphomas Therapies- Etoposide, Prednisolone, Romidepsin, Ixazomib, Chidamide, and others.
  • Peripheral T-Cell Lymphomas Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Peripheral T-Cell Lymphomas Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Peripheral T-Cell Lymphomas Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Peripheral T-Cell Lymphomas Companies, Key Products and Unmet Needs

Table of Content

  1. Introduction
  2. Executive Summary
  3. Peripheral T-Cell Lymphomas (PTCL): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Peripheral T-Cell Lymphomas (PTCL) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Peripheral T-Cell Lymphomas (PTCL) Collaboration Deals
  9. Mid Stage Products (Phase II)
  10. HBI-8000: HUYA Bioscience International
  11. F520: Shandong New Time Pharmaceutical Co., LTD
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. YY-20394: Shanghai YingLi Pharmaceutical Co. Ltd.
  15. Drug profiles in the detailed report…..
  16. Pre-clinical and Discovery Stage Products
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Peripheral T-Cell Lymphomas (PTCL) Key Companies
  20. Peripheral T-Cell Lymphomas (PTCL) Key Products
  21. Peripheral T-Cell Lymphomas (PTCL)- Unmet Needs
  22. Peripheral T-Cell Lymphomas (PTCL)- Market Drivers and Barriers
  23. Peripheral T-Cell Lymphomas (PTCL)- Future Perspectives and Conclusion
  24. Peripheral T-Cell Lymphomas (PTCL) Analyst Views
  25. Peripheral T-Cell Lymphomas (PTCL) Key Companies
  26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Categories